A PPARγ mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus

Molecular and Cellular Endocrinology

Volumn 162, Issue 1-2, 2000, Pages 57-67

  Berger, Joel ^a   Patel, Hansa V ^b   Woods, John ^a   Hayes, Nancy S ^a   Parent, Stephen A ^a   Clemas, Joseph ^a   Leibowitz, Mark D ^a   Elbrecht, Alex ^a   Rachubinski, Richard A ^c   Capone, John P ^b   Moller, David E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antidiabetic agents; Dominant negative mutant; Nuclear receptors; Peroxisome proliferator activated receptors; Thiazolidinediones

Indexed keywords

ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOID X RECEPTOR; CELL RECEPTOR; COMPLEMENTARY DNA; LIGAND; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; COMPLEX FORMATION; ELECTROPHORETIC MOBILITY; ENHANCER REGION; FATTY ACID OXIDATION; GENE MUTATION; GENETIC TRANSFECTION; LIPID METABOLISM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR AFFINITY; REPORTER GENE; TISSUE DISTRIBUTION; ANIMAL; CELL NUCLEUS; CELL STRAIN COS1; CHEMISTRY; DIMERIZATION; GENE DELETION; GENETICS; HUMAN; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN QUATERNARY STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; BASE SEQUENCE; CELL NUCLEUS; COS CELLS; DIMERIZATION; DNA, COMPLEMENTARY; HUMANS; LIGANDS; MUTATION; PHENOTYPE; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0034712589     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(00)00211-2     Document Type: Article

References (47)

1. Allan G.F., Xiaohua L., Tsai S.Y., Weigel N.L., Edwards D.P., Tsai M.-J., O'Malley B.W. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J. Biol. Chem. 267:1992;19513-19520.
2. Barettino D., Ruiz M.V., Stunnenberg H.G. Characterization of the ligand-dependent transactivation domain of thyroid hormone receptor. EMBO J. 13:1994;3009-3049.
3. Berger J., Bailey P., Biswas C., Cullinan C.A., Doebber T.W., Hayes N.S., Saperstein R., Smith R.G., Leibowitz M.D. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 137:1996;4189-4195.
4. Berger J., Leibowitz M.D., Doebber T.W., Elbrecht A., Zhang B., Zhou G., Biswas C., Cullinan C.A., Hayes N.S., Li Y., Tanen M., Ventre J., Wu M.S., Berger G.D., Mosley R., Marquis R., Santini C., Sahoo S.P., Tolman R.L., Smith R.G., Moller D.E. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J. Biol. Chem. 274:1999;6718-6725.
5. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α Nature. 375:1995;377-382.
6. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors: tissue distribution of PPARα, β and γ in the adult rat. Endocrinology. 137:1995;354-366.
7. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., Wahli W. The PPARα-leukotriene B4 pathway to inflammation control. Nature. 384:1996;39-43.
8. Didier A., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., Staels B., Auwerx J., LaVille M., Vidal H. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver×receptor-α in humans. Diabetes. 46:1997;1319-1327.
9. Dowell P., Peterson V.J., Zabriskie T.M., Leid M. Ligand-induced peroxisome proliferator-activated receptor α conformational change. J. Biol. Chem. 272:1997;2013-2020.
10. Dreyer C., Keller H., Mahfoudi A., Laudet V., Krey G., Wahli W. Positive regulation of peroxisomal β-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol. Cell. 77:1993;67-77.
11. Durand B., Saunders M., Gaundon C., Roy B., Losson R., Chambon P. Activation function of retinoic acid receptor and 9-cis-retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and of the nature of the response element. EMBO J. 13:1994;5370-5382.
12. Elbrecht A., Chen Y., Cullinan C.A., Hayes N., Leibowitz M.D., Moller D.E., Berger J. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem. Biophys. Res. Commun. 224:1996;431-437.
13. Ez-Zoubir A., Bonino F., Ailhaud G., Abumrad N.A., Grimaldi P.A. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. J. Biol. Chem. 270:1995;2367-2371.
14. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-Δ12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ Cell. 83:1995;803-812.
15. Gottlicher M., Widmark E., Li Q., Gustafsson J.A. Fatty acids activate the clofibric acid activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 89:1992;4653-4657.
16. Greene M.E., Blumberg B., McBride O.W., Yi H.F., Kronquist K., Kwan K., Hsieh L., Greene G., Nimer S.D. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hemapoietic cells and chrosomal mapping. Gene Exp. 4:1995;281-299.
17. Issemann I., Prince R.A., Tugwood J.D., Green S. The peroxisome proliferator activated receptor: retinoid×receptor heterodimer is activated by fatty acid and fibrate hypolipidaemic drugs. J. Mol. Endocrinol. 11:1993;37-47.
18. Jow L., Mukherjee R. The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPARα and thyroid receptor receptors. J. Biol. Chem. 270:1995;3836-3840.
19. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S.-C., Heyman R.A., Rose D.W., Glass C.K., Rosenfeld M.G. A CBP integrator complex mediates transcriptionnal activation and AP-1 inhibition by nuclear receptors. Cell. 85:1996;403-414.
20. Keller H., Wahli W. Peroxisome proliferator-activated receptors. Trends Endocrinol. Metab. 4:1993;291-296.
21. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptors-retinoid×receptor heterodimers. Proc. Natl. Acad. Sci. U.S.A. 90:1993;2160-2164.
22. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., Evans R.M. Convergence of 9-cis-retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature. 358:1992;771-774.
23. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., Umesono K., Evans R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 91:1994;7355-7359.
24. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehman J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:1995;813-819.
25. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisomal proliferator-activated receptor γ J. Biol. Chem. 270:1995;12953-12956.
26. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark E., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell. 83:1995;835-839.
27. Masuyama H., Brownfield C.M., St-Arnaud R., MacDonald P.N. Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. Mol. Endocrinol. 11:1997;1507-1517.
28. Minucci S., Zand D.J., Dey A., Marks M.S., Nagata T., Grippo J.F., Ozato K. Dominant negative retinoid×receptor β inhibits retinoic acid-responsive gene regulation in embryonal carcinoma cells. Mol. Cell. Biol. 14:1994;360-372.
29. Miyata K.S., McCaw S.E., Patel H.V., Rachubinski R.A., Capone J.P. The orphan nuclear hormone receptor LXR α interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signalling. J. Biol. Chem. 271:1996;9189-9192.
30. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 395:1998;137-143.
31. Osumi T., Wen J.K., Hashimoto T. Two cis-acting regulatory elements in the peroxisome proliferator-responsive element enhancer region of rat acyl-CoA oxidase gene. Biochem. Biophys. Res. Commun. 175:1991;866-871.
32. Renaud J.-P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature. 378:1995;681-689.
33. Schmidt, A., Endo, N., Rutledge, S.J., Vogel, R., Shinar, D., Rodan, G.A., 1992. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acid, Mol. Endocrinol. 1634-1641.
34. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R., Briggs M., Cayet D., Deeb S., Staels B., Auwerx J. PPARα and PPARγ activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:1996;5336-5348.
35. Schoonjans K., Staels B., Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta. 1302:1996;93-109.
36. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1994;1224-1234.
37. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid activated transcription factor. Cell. 79:1994;1147-1156.
38. Tontonoz P., Hu E., Devine J., Geale E.G., Spiegelman B.M. PPARγ2 regulates adipose expression of the phospoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 15:1995;351-357.
39. Tugwood J.D., Isseman I., Anderson R.G., Bundell K.R., McPheat W.L., Green S. The mouse peroxisome-proliferator-activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11:1992;433-439.
40. Vidal-Puig A., Jimenex-Linan M., Hamann A., Lowell B.B., Hu E., Spiegelman B.M., Flier J.S., Moller D.E. Regulation of PPARγ gene expression in vivo by nutrition and obesity. J. Clin. Invest. 97:1996;2553-2561.
41. Voegel J.J., Heine M.J.S., Zechel C., Chambon P., Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15:1996;3667-3675.
42. Werman A., Hollenberg A., Solanes G., Bjorbaek C., Vidal-Puig A.J., Flier J.S. Ligand-independent activation domain in the N-terminus of peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 272:1997;20230-20235.
43. Wilson T.M., Cobb J.E., Cowan D.J., Wiethe R.W., Correa I.D., Prakash S.R., Beck K.D., Moore L.B., Kliewer S.A., Lehmann J.M. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39:1996;665-668.
44. Yang X.J., Ogryzko V.V., Nishikawa J., Howard B.H., Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature. 382:1996;319-324.
45. Zhu Y., Alvares K., Huang Q., Sambasiva Rao M., Reddy J.K. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J. Biol. Chem. 268:1993;26817-26820.
46. Zhu Y., Qi C., Korenberg J.R., Chen X.N., Noya D., Sambasiva Rao M., Reddy J.K. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc. Natl. Acad. Sci. U.S.A. 92:1995;7921-7925.
47. Zierath J.R., Ryder J.W., Doebber T., Woods J., Wu M., Ventre J., Li Z., McCrary C., Berger J., Zhang B., Moller D.E. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology. 139:1998;5034-5041.